Opinion Summary: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap

Oral Argument Re-Listen: Keathley v. Buddy Ayers | Nondisclosure Doesn't Lead to Lawsuit Dismissal

Keathley v. Buddy Ayers Construction, Inc. | Case No. 25-6 | Docket Link: Here [https://www.supremecourt.gov/search.aspx?filename=/docket/docketfiles/html/public/25-6.html] | Argued: 3/24/2026 | Decided: 6/11/2026 Oral Advocates: 1. Petitioner (Keathley): Gregory G. Garre of Latham and Watkins 2. United States (as Amicus Curiae Supporting Vacatur): Frederick Liu, Assistant to the Solicitor General, Department of Justice 3. Respondent (Buddy Ayers Construction): William M. Jay of Goodwin Proctor Overview: A bankruptcy debtor's failure to disclose a personal-injury lawsuit triggered the Fifth Circuit's rigid two-factor estoppel test, splitting federal circuits over whether courts must examine all circumstances or presume bad faith from knowledge and motive alone. Question Presented: Whether courts must examine the totality of circumstances — not just two factors — to determine if a bankruptcy debtor's omission of a lawsuit qualifies as inadvertent. Posture: District court and Fifth Circuit dismissed Keathley's personal-injury lawsuit under rigid two-factor judicial estoppel rule. Main Arguments: * Petitioner Keathley: (1) Courts must examine all circumstances before concluding a bankruptcy omission reflects intentional concealment; (2) The Fifth Circuit's test conflates theoretical motive with actual bad faith, eliminating any real inadvertence exception; (3) Blocking honest debtors' lawsuits rewards tortfeasors and destroys assets creditors could recover. * Respondent Buddy Ayers Construction: (1) Objective inconsistency — not subjective bad intent — supplies the basis for judicial estoppel; (2) The inadvertence exception covers only objectively verifiable errors, not every non-malicious explanation a debtor offers; (3) A multi-factor holistic test eliminates deterrence, invites abuse, and guts the bankruptcy disclosure system. Holding: Courts must examine the totality of circumstances surrounding a debtor's bankruptcy omission to determine whether that omission qualifies as inadvertent or mistaken for purposes of judicial estoppel; the Fifth Circuit erred by artificially restricting its inquiry to only two factors. Voting Breakdown: 9-0. Justice Jackson delivered the opinion for a unanimous Court. Justice Thomas filed a concurring opinion, in which Justice Gorsuch joined. Justice Sotomayor filed a concurring opinion. Vacated and remanded. Opinion: Here [https://www.supremecourt.gov/opinions/25pdf/25-6_d1o2.pdf] Majority Reasoning: * (1) Judicial estoppel functions as an equitable doctrine, and equity demands case-by-case flexibility — not a mechanical two-factor checklist that blocks courts from considering all available evidence; * (2) The Fifth Circuit's test fails both as too rigid — barring courts from looking beyond two factors — and too broad — those two factors apply to virtually every bankruptcy omission, making the exception meaningless; * (3) Courts must weigh all circumstances — including prompt correction, absence of actual benefit, counsel's knowledge, and local bankruptcy practice — to determine whether an omission truly resulted from inadvertence. Separate Opinions: * Justice Thomas (concurring, joined by Gorsuch): Joins majority in full but questions whether federal courts hold any authority to apply judicial estoppel at all; the doctrine lacks statutory, procedural, or founding-era support and merits reexamination in a future case. * Justice Sotomayor (concurring): Agrees with majority but argues judicial estoppel may never appropriately apply during open bankruptcy proceedings — bankruptcy courts already hold targeted remedies that serve the doctrine's goals without destroying debtors' claims. Implications: * (1) Debtors who forget to disclose post-petition claims now receive a full-facts review before courts bar their lawsuits; * (2) Personal-injury defendants lose the automatic kill switch that a bankruptcy filing once supplied in Fifth and Tenth Circuit courts; * (3) Thomas and Gorsuch's concurrence opens the door to a future challenge to judicial estoppel's existence in federal courts entirely. The Fine Print: * 11 U.S.C. § 541(a)(1): "all legal or equitable interests of the debtor in property as of the commencement" of the bankruptcy case, including pending and unliquidated claims against third parties. * Official Form 106A/B, Schedule A/B: Property, Pt. 4, Question 33: Debtors must disclose "[c]laims against third parties, whether or not [the debtor] ha[s] filed a lawsuit or made a demand for payment." Primary Cases: * New Hampshire v. Maine (2001): Established the modern federal framework for judicial estoppel and left open whether inadvertence or mistake may block the doctrine's application. * Holmberg v. Armbrecht (1946): Confirmed that equitable doctrines "eschew mechanical rules" and depend on flexibility, requiring case-by-case analysis rather than rigid checklists. Timestamps: [00:00:00] Argument Preview [00:01:18] Argument Begins [00:01:26] Keathley Opening Statement [00:03:33] Keathley Free for All Questions [00:18:46] Keathley Round Robin Questions [00:33:09] United States Opening Statement [00:34:28] United States Free for All Questions [00:42:11] United States Round Robin Questions [00:47:24] Buddy Ayers Opening Statement [00:49:27] Buddy Ayers Free for All Questions [01:09:04] Buddy Ayers Round Robin Questions [01:09:13] Keathley Rebuttal

Opinion Summary: Keathley v. Buddy Ayers | Nondisclosure Doesn't Lead to Lawsuit Dismissal

Keathley v. Buddy Ayers Construction, Inc. | Case No. 25-6 | Docket Link: Here [https://www.supremecourt.gov/search.aspx?filename=/docket/docketfiles/html/public/25-6.html] | Argued: 3/24/2026 | Decided: 6/11/2026 Overview: A bankruptcy debtor's failure to disclose a personal-injury lawsuit triggered the Fifth Circuit's rigid two-factor estoppel test, splitting federal circuits over whether courts must examine all circumstances or presume bad faith from knowledge and motive alone. Question Presented: Whether courts must examine the totality of circumstances — not just two factors — to determine if a bankruptcy debtor's omission of a lawsuit qualifies as inadvertent. Posture: District court and Fifth Circuit dismissed Keathley's personal-injury lawsuit under rigid two-factor judicial estoppel rule. Main Arguments: * Petitioner Keathley: (1) Courts must examine all circumstances before concluding a bankruptcy omission reflects intentional concealment; (2) The Fifth Circuit's test conflates theoretical motive with actual bad faith, eliminating any real inadvertence exception; (3) Blocking honest debtors' lawsuits rewards tortfeasors and destroys assets creditors could recover. * Respondent Buddy Ayers Construction: (1) Objective inconsistency — not subjective bad intent — supplies the basis for judicial estoppel; (2) The inadvertence exception covers only objectively verifiable errors, not every non-malicious explanation a debtor offers; (3) A multi-factor holistic test eliminates deterrence, invites abuse, and guts the bankruptcy disclosure system. Holding: Courts must examine the totality of circumstances surrounding a debtor's bankruptcy omission to determine whether that omission qualifies as inadvertent or mistaken for purposes of judicial estoppel; the Fifth Circuit erred by artificially restricting its inquiry to only two factors. Voting Breakdown: 9-0. Justice Jackson delivered the opinion for a unanimous Court. Justice Thomas filed a concurring opinion, in which Justice Gorsuch joined. Justice Sotomayor filed a concurring opinion. Vacated and remanded. Opinion: Here [https://www.supremecourt.gov/opinions/25pdf/25-6_d1o2.pdf] Majority Reasoning: * (1) Judicial estoppel functions as an equitable doctrine, and equity demands case-by-case flexibility — not a mechanical two-factor checklist that blocks courts from considering all available evidence; * (2) The Fifth Circuit's test fails both as too rigid — barring courts from looking beyond two factors — and too broad — those two factors apply to virtually every bankruptcy omission, making the exception meaningless; * (3) Courts must weigh all circumstances — including prompt correction, absence of actual benefit, counsel's knowledge, and local bankruptcy practice — to determine whether an omission truly resulted from inadvertence. Separate Opinions: * Justice Thomas (concurring, joined by Gorsuch): Joins majority in full but questions whether federal courts hold any authority to apply judicial estoppel at all; the doctrine lacks statutory, procedural, or founding-era support and merits reexamination in a future case. * Justice Sotomayor (concurring): Agrees with majority but argues judicial estoppel may never appropriately apply during open bankruptcy proceedings — bankruptcy courts already hold targeted remedies that serve the doctrine's goals without destroying debtors' claims. Implications: * (1) Debtors who forget to disclose post-petition claims now receive a full-facts review before courts bar their lawsuits; * (2) Personal-injury defendants lose the automatic kill switch that a bankruptcy filing once supplied in Fifth and Tenth Circuit courts; * (3) Thomas and Gorsuch's concurrence opens the door to a future challenge to judicial estoppel's existence in federal courts entirely. The Fine Print: * 11 U.S.C. § 541(a)(1): "all legal or equitable interests of the debtor in property as of the commencement" of the bankruptcy case, including pending and unliquidated claims against third parties. * Official Form 106A/B, Schedule A/B: Property, Pt. 4, Question 33: Debtors must disclose "[c]laims against third parties, whether or not [the debtor] ha[s] filed a lawsuit or made a demand for payment." Primary Cases: * New Hampshire v. Maine (2001): Established the modern federal framework for judicial estoppel and left open whether inadvertence or mistake may block the doctrine's application. * Holmberg v. Armbrecht (1946): Confirmed that equitable doctrines "eschew mechanical rules" and depend on flexibility, requiring case-by-case analysis rather than rigid checklists.

Oral Argument Re-Listen: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here [https://www.supremecourt.gov/docket/docketfiles/html/public/24-889.html] | Argued: 04/29/2026 | Decided: 06/04/2026 Oral Advocates: * Petitioners (Hikma): Charles B. Klein of Winston & Strawn LLP * Amicus Curiae (United States): Malcolm L. Stewart of the Department of Justice * Respondents (Amarin Pharma): Michael R. Huston of Perkins Coie LLP Overview: Amarin's cardiovascular drug patent faced challenge when generic maker Hikma launched a skinny-label version and marketed it through statements Amarin claimed encouraged doctors to prescribe the generic for the still-patented heart indication. Question Presented: Whether a generic drug maker's marketing statements plausibly constitute "active steps" inducing patent infringement under 35 U.S.C. §271(b). Posture: District Court dismissed; Federal Circuit reversed; Supreme Court reversed and remanded. Main Arguments: Petitioner (Hikma): * (1) Statements fully consistent with lawful skinny-label marketing cannot constitute active inducement under §271(b); * (2) Federal law mandated the label's contents, making legal compliance an obvious alternative explanation that forecloses liability; * (3) The Federal Circuit's physician-reading standard would destroy the Hatch-Waxman section viii pathway and expose generics to devastating litigation risk. Respondent (Amarin): * (1) Hikma's totality of statements — repeatedly invoking "generic Vascepa," using an overbroad therapeutic category, and touting Vascepa's billion-dollar sales — plausibly encouraged infringing use; * (2) Amarin spent $300 million discovering the cardiovascular indication and patent law must protect that investment from free-riders; * (3) Seven other generic manufacturers avoided liability by accurately describing only their narrow approved uses, demonstrating Hikma's conduct fell outside normal practice. Holding: Amarin failed to state a claim for active inducement in violation of §271(b); none of Hikma's alleged statements — individually or in totality — plausibly constituted active steps encouraging infringement of Amarin's cardiovascular-use patents. Voting Breakdown: 9-0. Justice Jackson delivered the opinion for a unanimous Court. No Justice filed a separate opinion. Federal Circuit reversed and remanded. Opinion: Here [https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf] Majority Reasoning: * (1) Active inducement requires affirmative steps to encourage infringement — not merely statements physicians could read as instructions to infringe; * (2) Hikma's label reflected legal compliance under the duty of sameness, its "generic Vascepa" description reflected standard industry practice, and omissions alone cannot support active inducement; * (3) Website category descriptions, patient leaflet warnings, and investor press release sales figures lacked the clear, affirmative message inducement demands. Separate Opinions: None. The decision was unanimous. Implications: * (1) Generic manufacturers may use the Hatch-Waxman skinny-label pathway without automatic inducement liability for routine commercial communications; * (2) Brand manufacturers must plead specific affirmative acts of encouragement — not inferences drawn from vague statements or omissions; * (3) The active inducement framework now applies with fresh clarity across all patent-holding industries. The Fine Print: * 35 U.S.C. §271(b): "Whoever actively induces infringement of a patent shall be liable as an infringer." * 21 U.S.C. §355(j)(2)(A)(v): Requires a generic drug application to contain "information to show that the labeling proposed for the new drug is the same as the labeling approved for the [reference] listed drug . . . except for changes required because of differences approved under [applicable regulations]." Primary Cases: * Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd. (2005): Active inducement requires purposeful, culpable expression and conduct designed to stimulate infringement; distributing a product capable of both infringing and non-infringing uses does not, alone, impose liability. * Bell Atlantic Corp. v. Twombly (2007): A complaint must plead facts supporting a plausible claim for relief; allegations carrying obvious alternative lawful explanations fail to clear the plausibility bar.

Opinion Summary: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here [https://www.supremecourt.gov/docket/docketfiles/html/public/24-889.html] | Argued: 04/29/2026 | Decided: 06/04/2026 Overview: Amarin's cardiovascular drug patent faced challenge when generic maker Hikma launched a skinny-label version and marketed it through statements Amarin claimed encouraged doctors to prescribe the generic for the still-patented heart indication. Question Presented: Whether a generic drug maker's marketing statements plausibly constitute "active steps" inducing patent infringement under 35 U.S.C. §271(b). Posture: District Court dismissed; Federal Circuit reversed; Supreme Court reversed and remanded. Main Arguments: Petitioner (Hikma): * (1) Statements fully consistent with lawful skinny-label marketing cannot constitute active inducement under §271(b); * (2) Federal law mandated the label's contents, making legal compliance an obvious alternative explanation that forecloses liability; * (3) The Federal Circuit's physician-reading standard would destroy the Hatch-Waxman section viii pathway and expose generics to devastating litigation risk. Respondent (Amarin): * (1) Hikma's totality of statements — repeatedly invoking "generic Vascepa," using an overbroad therapeutic category, and touting Vascepa's billion-dollar sales — plausibly encouraged infringing use; * (2) Amarin spent $300 million discovering the cardiovascular indication and patent law must protect that investment from free-riders; * (3) Seven other generic manufacturers avoided liability by accurately describing only their narrow approved uses, demonstrating Hikma's conduct fell outside normal practice. Holding: Amarin failed to state a claim for active inducement in violation of §271(b); none of Hikma's alleged statements — individually or in totality — plausibly constituted active steps encouraging infringement of Amarin's cardiovascular-use patents. Voting Breakdown: 9-0. Justice Jackson delivered the opinion for a unanimous Court. No Justice filed a separate opinion. Federal Circuit reversed and remanded. Opinion: Here [https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf] Majority Reasoning: * (1) Active inducement requires affirmative steps to encourage infringement — not merely statements physicians could read as instructions to infringe; * (2) Hikma's label reflected legal compliance under the duty of sameness, its "generic Vascepa" description reflected standard industry practice, and omissions alone cannot support active inducement; * (3) Website category descriptions, patient leaflet warnings, and investor press release sales figures lacked the clear, affirmative message inducement demands. Separate Opinions: None. The decision was unanimous. Implications: * (1) Generic manufacturers may use the Hatch-Waxman skinny-label pathway without automatic inducement liability for routine commercial communications; * (2) Brand manufacturers must plead specific affirmative acts of encouragement — not inferences drawn from vague statements or omissions; * (3) The active inducement framework now applies with fresh clarity across all patent-holding industries. The Fine Print: * 35 U.S.C. §271(b): "Whoever actively induces infringement of a patent shall be liable as an infringer." * 21 U.S.C. §355(j)(2)(A)(v): Requires a generic drug application to contain "information to show that the labeling proposed for the new drug is the same as the labeling approved for the [reference] listed drug . . . except for changes required because of differences approved under [applicable regulations]." Primary Cases: * Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd. (2005): Active inducement requires purposeful, culpable expression and conduct designed to stimulate infringement; distributing a product capable of both infringing and non-infringing uses does not, alone, impose liability. * Bell Atlantic Corp. v. Twombly (2007): A complaint must plead facts supporting a plausible claim for relief; allegations carrying obvious alternative lawful explanations fail to clear the plausibility bar. Oral Advocates: * Petitioners (Hikma): Charles B. Klein of Winston & Strawn LLP * Amicus Curiae (United States): Malcolm L. Stewart of the Department of Justice * Respondents (Amarin Pharma): Michael R. Huston of Perkins Coie LLP

Oral Argument Re-Listen: Sripetch v. SEC | Victimless Fraudsters Can't Keep Profits

Sripetch v. Securities and Exchange Commission | Case No. 25-466 | Docket Link: Here [https://www.supremecourt.gov/docket/docketfiles/html/public/25-466.html] | Argued: April 20, 2026 | Decided: June 4, 2026 Overview: The Supreme Court resolves a circuit split over whether the SEC must prove investors lost money before ordering disgorgement — preserving billions in annual securities enforcement power. Question Presented: Whether the SEC may seek disgorgement without proving investors suffered pecuniary harm. Posture: Ninth Circuit affirmed disgorgement without pecuniary harm; Supreme Court granted certiorari to resolve circuit split. Main Arguments: * Sripetch: (1) Disgorgement without pecuniary harm functions as an unlawful penalty, not equitable relief; (2) Congress's 2021 amendments ratified Liu's disgorgement definition, requiring restoration of funds to actual victims; (3) SEC's reading creates statutory anomalies and lets the agency circumvent jury-trial and procedural safeguards attached to civil penalties. * SEC: (1) Disgorgement targets the wrongdoer's gain, not the victim's loss — no loss showing required; (2) Congress deliberately omitted the "for the benefit of investors" language from the 2021 statute, eliminating any pecuniary-harm prerequisite; (3) "Unjust enrichment" in the 2021 text carries a common-law meaning that never required proof of monetary loss. Holding: The SEC may obtain a disgorgement award without proving investors suffered pecuniary loss. Traditional equitable principles tie the remedy to the defendant's wrongful gain from invading legally protected interests — not to any documented financial loss by the victim. Ninth Circuit affirmed. Voting Breakdown: 9-0. Justice Gorsuch authored the majority opinion joined by Chief Justice Roberts and Justices Thomas, Sotomayor, Kagan, Barrett, Kavanaugh, and Jackson. Justice Thomas filed a concurring opinion. Ninth Circuit affirmed. Opinion: Here [https://www.supremecourt.gov/opinions/25pdf/25-466_5i26.pdf] Majority Reasoning: * (1) Traditional equitable principles — confirmed across centuries of case law and the Restatements — measure disgorgement by the defendant's wrongful gain, not the victim's financial loss; no pecuniary harm requirement ever existed in equity; * (2) Liu's "for victims" requirement drew from traditional equitable principles; those principles define a victim as someone whose legally protected interests the wrongdoer invaded, not someone who documented a financial loss; * (3) When a defendant enriched himself without leaving the plaintiff financially worse off, equity prefers stripping the wrongdoer of unjust gains over allowing him to benefit from misconduct. Separate Opinions: * Justice Thomas (concurring): Agreed with the outcome but argued Congress's 2021 amendments transformed disgorgement into a legal remedy; urged the Court to recognize, in a future case, that the Seventh Amendment requires a jury trial for SEC disgorgement actions. Implications: * (1) The SEC's multi-billion-dollar disgorgement toolkit survives intact — fraudsters cannot escape profit-stripping by structuring schemes so victims lose no documentable money; * (2) The "nobody lost money" defense no longer shields securities violators from disgorgement; * (3) Justice Thomas's concurrence invites a future Seventh Amendment jury-trial challenge to SEC disgorgement under the 2021 statute. The Fine Print: * 15 U.S.C. § 78u(d)(5): "In any action or proceeding brought or instituted by the Commission under any provision of the securities laws, the Commission may seek, and any Federal court may grant, any equitable relief that may be appropriate or necessary for the benefit of investors." * 15 U.S.C. § 78u(d)(7): "In any action or proceeding brought by the Commission under any provision of the securities laws, the Commission may seek, and any Federal court may order, disgorgement." Primary Cases: * Liu v. SEC (2020): The Supreme Court held SEC disgorgement must not exceed a wrongdoer's net profits and must go "for victims" — the foundational ruling this decision extended. * SEC v. Govil (2d Cir. 2023): The Second Circuit required proof of investor pecuniary harm before disgorgement, creating the circuit conflict the Supreme Court granted certiorari to resolve. Oral Advocates: * Petitioners (Sripetch): Daniel L. Geyser of Haynes and Boone LLP * Respondents (SEC): Malcolm L. Stewart of the Department of Justice